Abstract
Background: This study aims to compare the outcomes of psoriasis hospitalizations with and without joint involvement. The primary outcome was inpatient mortality, while secondary outcomes were hospital length of stay (LOS) and total hospital charges.Methods: Data were abstracted from the National Inpatient Sample (NIS) 2016 and 2017 databases. The NIS was searched for psoriasis hospitalizations with and without joint involvement as principal or secondary diagnosis using the International Classification of Diseases, tenth revision (ICD-10) codes. Psoriasis hospitalizations for adult patients (aged ≥18 years) from the above groups were identified. Multivariate logistic and linear regression analysis was used to adjust for confounders for the primary and secondary outcomes, respectively.Results: There were over 71 million discharges included in the combined 2016 and 2017 NIS database. A total of 323,405 hospitalizations were for adult patients with either a principal or secondary ICD-10 code for psoriasis. Of these hospitalizations, 77,980 (24.11%) had joint involvement. Psoriasis hospitalizations with joint involvement had similar inpatient mortality (1.42% vs. 1.78%, adjusted odds ratio (AOR): 0.89, 95% CI: 0.76-1.05, p=0.159) compared with those without joint involvement. Psoriasis with joint involvement hospitalizations had a decrease in adjusted mean LOS of 0.15 days (95% CI: 0.26-0.04, p=0.007) compared with the group without joint involvement. Psoriasis with joint involvement hospitalizations had an increase in adjusted mean total hospital charges of $3,655 (95% CI: 2,146-5,164; p<0.0001) compared with the group without joint involvement.Conclusions: Hospitalizations for psoriasis with and without joint involvement have similar inpatient mortality. However, joint involvement increases total hospital charges, which increases the burden to the health care system.
Highlights
Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting over seven million adults in the United States and is associated with substantial morbidity and mortality
A recent review of 20 epidemiologic studies found that the reported proportion of psoriatic arthritis among psoriasis patients in the United States ranges from 7% to 26% [6], Europe with 0.02%-0.42%, Japan is approximately 0.001%, and China is 0.02% [7,8,9,10,11,12]
A total of 323,405 hospitalizations were for adult patients with either a principal or secondary International Classification of Diseases (ICD-10) code for psoriasis
Summary
Immune-mediated inflammatory skin disease affecting over seven million adults in the United States and is associated with substantial morbidity and mortality. It ranges in severity from a few scattered red, scaly plaques to involvement of almost the entire body surface. A recent review of 20 epidemiologic studies found that the reported proportion of psoriatic arthritis among psoriasis patients in the United States ranges from 7% to 26% [6], Europe with 0.02%-0.42%, Japan is approximately 0.001%, and China is 0.02% [7,8,9,10,11,12]. The primary outcome was inpatient mortality, while secondary outcomes were hospital length of stay (LOS) and total hospital charges
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
